ea0049ep641 | Neuroendocrinology | ECE2017
Casamitjana Laia
, Olga Gimenez-Palop
, Raquel Corripio
, Rocio Pareja
, Marta Hurtado
, Elisabet Gabau
, Jesus Cobo
, Eugenio Berlanga
, Albert Cano
, Lara Albert
, Mercedes Rigla
, Assumpta Caixas
Background: Prader-Willi syndrome (PWS) is a rare genetic disorder evolving morbid obesity and growth hormone deficiency (GHD). Testing GH-IGF1 axis is required before treatment with rhGH in adults with PWS (1). The most common used tests in these patients are GHRH+arginine (GHRH+a) and insulin tolerance test. There are no prospective data for glucagon test (GT) in comparison to GHRH+a in adults with PWS. Mechanism by which GT causes GH release remains unclear, glucagon-induce...